| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009583407 |
| P356 | DOI | 10.1186/1471-2407-14-578 |
| P932 | PMC publication ID | 4133074 |
| P698 | PubMed publication ID | 25106741 |
| P5875 | ResearchGate publication ID | 264633467 |
| P2093 | author name string | Yi Wang | |
| Mo Li | |||
| Chao Fu | |||
| Chao Zhang | |||
| Wei Zhang | |||
| Fan Wu | |||
| Jun Qi | |||
| Xiaobing Wang | |||
| Teng Wang | |||
| Jianyu Rao | |||
| Yanfen Li | |||
| Dongwan Cheng | |||
| Wenya Zhao | |||
| Haimei Tian | |||
| P2860 | cites work | MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily | Q24317134 |
| Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury | Q24554213 | ||
| Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway | Q24620497 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases | Q28221222 | ||
| ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer | Q28270163 | ||
| Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer | Q28273473 | ||
| Pancreatic cancer | Q29622871 | ||
| Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum | Q30452357 | ||
| Serum Biomarker Panels for the Detection of Pancreatic Cancer | Q30499531 | ||
| Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer | Q33723662 | ||
| Macrophage inhibitory cytokine-1 regulates melanoma vascular development | Q33882542 | ||
| Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality | Q34072831 | ||
| Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer | Q34099900 | ||
| Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer | Q34577084 | ||
| Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors | Q34732848 | ||
| Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy | Q35051499 | ||
| Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer | Q36481328 | ||
| Current therapies and advances in the treatment of pancreatic cancer | Q36489481 | ||
| Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative | Q37351464 | ||
| A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer | Q37696690 | ||
| Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells | Q38494175 | ||
| The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. | Q39492314 | ||
| Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity | Q39946272 | ||
| Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. | Q40015389 | ||
| Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis | Q40359911 | ||
| Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers | Q40568605 | ||
| Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression | Q40884700 | ||
| Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family | Q41037584 | ||
| Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? | Q43690125 | ||
| Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. | Q44564112 | ||
| Diagnostic Validity of Serum Macrophage Inhibitor Cytokine and Tissue Polypeptide-Specific Antigen in Pancreatobiliary Diseases | Q44970452 | ||
| Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. | Q45059768 | ||
| Pancreatic cancer in the general population: Improvements in survival over the last decade. | Q54438493 | ||
| Is CA242 really a new tumour marker for pancreatic adenocarcinoma? | Q72357241 | ||
| MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma | Q73653083 | ||
| Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system | Q73784537 | ||
| Secreted and cell surface genes expressed in benign and malignant colorectal tumors | Q74590931 | ||
| The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer | Q81377177 | ||
| Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9 | Q82332973 | ||
| Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer | Q84472567 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macrophage | Q184204 |
| adenocarcinoma | Q356033 | ||
| biomarker | Q864574 | ||
| pancreatic ductal carcinoma | Q8263002 | ||
| P304 | page(s) | 578 | |
| P577 | publication date | 2014-08-08 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma | |
| P478 | volume | 14 |
| Q52599666 | A Meta-Analysis of Genome-Wide Association Studies of Growth Differentiation Factor-15 Concentration in Blood |
| Q38780449 | A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT). |
| Q64233995 | Advances in pancreatic cancer biomarkers |
| Q64099112 | Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis |
| Q37564619 | Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics |
| Q33648690 | Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer |
| Q38670577 | Current and future biomarkers for pancreatic adenocarcinoma |
| Q52316138 | Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines. |
| Q51298601 | Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. |
| Q64967157 | Elevated circulating macrophage inhibitory cytokine 1 is a biological marker for the diagnosis and prognosis of osteosarcoma. |
| Q92973308 | GDF-15 in solid vs non-solid treatment-naïve malignancies |
| Q37702121 | GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway |
| Q47104373 | GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury |
| Q52630342 | GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer. |
| Q36729546 | GDF15 promotes EMT and metastasis in colorectal cancer |
| Q52326010 | GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. |
| Q47368220 | Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass |
| Q37267749 | Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells |
| Q37117179 | Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer |
| Q89793794 | Hypoxia Induces Growth Differentiation Factor 15 to Promote the Metastasis of Colorectal Cancer via PERK-eIF2α Signaling |
| Q58605578 | Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer |
| Q41955882 | Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags |
| Q61810548 | Inflammation and pancreatic cancer: An updated review |
| Q54944542 | Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies. |
| Q93197174 | Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort |
| Q26777379 | Molecular detection of pancreatic neoplasia: Current status and future promise |
| Q48163413 | Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. |
| Q47155954 | NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. |
| Q37694882 | New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer |
| Q41624551 | Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy |
| Q26768506 | Pancreatic Cancer Epidemiology, Detection, and Management |
| Q26777032 | Peptide-Based Treatment: A Promising Cancer Therapy |
| Q93114776 | Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia |
| Q36446724 | Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women |
| Q91639311 | Proteomic and genomic profiling of pancreatic cancer |
| Q52584324 | Proteomic biomarkers in body fluids associated with pancreatic cancer. |
| Q47129121 | Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation |
| Q92467866 | Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15 |
| Q58780532 | The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer |
| Q41504067 | The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer |
| Q60931608 | Utility of GDF-15 as a diagnostic biomarker in gastric cancer: an investigation combining GEO, TCGA and meta-analysis |
| Q47660322 | miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression |
Search more.